ABL1 and acute lymphoblastic leukemia: In the subgroup of BCR::ABL1 positive elderly ALL patients (>55 years), the combination of dasatinib with blinatumomab as a “chemotherapy-free” induction and consolidation regimen has recently been evaluated in the GIMEMA LAL 2116 D-ALBA trial [49].